New scan analysis aims to predict who will benefit from pancreatic cancer chemo
NCT ID NCT07243288
Summary
This study is testing a new way to analyze standard CT or MRI scans, called radiomics, to see if it can predict early on which patients with advanced pancreatic cancer will not respond to first-line chemotherapy. It involves looking back at the scans and records of 400 patients who have already been treated. The goal is to gather knowledge that could one day help doctors match patients to the most effective treatments sooner.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Cochin
Paris, 75014, France
Conditions
Explore the condition pages connected to this study.